EUVIMEDEUVIMED entdecken
Crossref

(+)-Magnoflorine suppresses osteoclastogenesis by regulating CCDC88A-associated signaling networks in estrogen-deficient osteoporosis

Wei Zhang, An-Zhu Wang, Xiang Li, Meng-Jiao Kang, Qian Liu, Jing-Ru Tian, Xiang-Yan Li, Ze-Yu Wang, Jin-Yue Zhao, Jia-Xing Fan, Shan Wang, Li-Hua Qin und 2 weitere

Phytomedicine · 2026

DOI: 10.1016/j.phymed.2026.158706 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2026. Verfasst von Wei Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Metabolic Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China; School of Basic Medicine, Gansu Uni…. Hauptthemen laut MEDLINE: Osteogenesis, Aporphines, Estrogens, Drugs, Chinese Herbal. Die Arbeit nennt 46 Literaturangaben. Gefördert von: China Academy of Chinese Medical Sciences, State Administration of Traditional Chinese Medicine of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Postmenopausal osteoporosis is primarily driven by estrogen deficiency-associated osteoclast hyperactivation, resulting in excessive bone resorption and progressive deterioration of bone microarchitecture. Although current anti-resorptive therapies are clinically effective, their long-term application remains limited by adverse effects. PURPOSE: This study aimed to evaluate the anti-osteoporotic effects of Gengnianshou Formula (GNS), identify its pharmacologically relevant absorbed constituents, and investigate the molecular mechanisms underlying its regulation of osteoclast differentiation under estrogen-deficient conditions. METHODS: An ovariectomized (OVX) rat model was used to evaluate the anti-osteoporotic effects of GNS in vivo. Bone microarchitecture and osteoclast activity were assessed using micro-CT, histological staining, ELISA, and western blotting. Serum and fecal metabolite profiling was performed by UPLC-MS/MS to identify exposure-related compounds. Candidate compounds were screened in RAW264.7 osteoclast differentiation models. Public transcriptomic datasets (GSE230665 and GSE246769) were integrated to identify key regulatory genes associated with osteoclastogenesis. CRISPR/Cas9-mediated knockout, molecular docking, microscale thermophoresis (MST), qPCR, immunofluorescence, and western blot analyses were performed for mechanistic validation. RESULTS: GNS significantly improved trabecular bone microarchitecture and reduced osteoclast activity in OVX rats. Exposure profiling identified adenosine, phellodendrine, and jatrorrhizine as prototype compounds in both serum and feces, whereas (+)-magnoflorine (MAG) was detected as a prototype in feces and as a demethylated metabolite in serum, indicating pharmacologically relevant MAG-related exposure. Functional screening identified (+)-MAG as the most potent inhibitor of osteoclast differentiation in vitro. Integrated transcriptomic analyses revealed that CCDC88A was an early-response gene associated with osteoporosis progression and osteoclast differentiation. CCDC88A deficiency attenuated osteoclastogenesis and altered CCDC88A-associated signaling responses. Moreover, molecular docking and MST analyses supported a direct interaction between (+)-MAG and CCDC88A, while CCDC88A depletion abolished the additional inhibitory effects of (+)-MAG on osteoclast differentiation. CONCLUSION: GNS effectively alleviated estrogen deficiency-associated bone loss by suppressing osteoclast activation. (+)-MAG was identified as an exposure-related bioactive constituent, and its anti-osteoclast effects were mediated through a CCDC88A-dependent regulatory mechanism. These findings provide new insights into osteoclast regulation and highlight GNS-derived compounds as potential therapeutic candidates for postmenopausal osteoporosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteogenesisAporphinesEstrogensDrugs, Chinese HerbalOsteoporosis, PostmenopausalOsteoporosisAnimalsFemaleOsteoclastsRats, Sprague-DawleyRatsOvariectomySignal TransductionMiceRAW 264.7 CellsCell DifferentiationBone ResorptionMolecular Docking SimulationDisease Models, Animal

Stichwörter der Autor:innen

(+)-MagnoflorineCCDC88AOsteoclast differentiationOvariectomy modelPostmenopausal osteoporosisWNT/β-catenin signaling

Substanzen

AporphinesmagnoflorineEstrogensDrugs, Chinese Herbal

Autor:innen und Institutionen

  • Institute of Metabolic Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China; School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
  • Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
  • The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • State Key Laboratory of Oral& Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi Key Laboratory of Stomatology; Department of Orthodontics, School of Stomatology,…
  • Northeast Asia Research Institute of Traditional Chinese Medicine, Ministry of Education, Changchun University of Chinese Medicine, Changchun, China.

Förderung

  • China Academy of Chinese Medical Sciences
  • State Administration of Traditional Chinese Medicine of the People's Republic of China

Zitieren

APA

Zhang, W., Wang, A. Z., Li, X., Kang, M. J., Liu, Q., Tian, J. R., Li, X. Y., Wang, Z. Y., Zhao, J. Y., Fan, J. X., Wang, S., Qin, L. H., Tong, X. L., & Zhao, L. H. (2026). (+)-Magnoflorine suppresses osteoclastogenesis by regulating CCDC88A-associated signaling networks in estrogen-deficient osteoporosis. Phytomedicine. https://doi.org/10.1016/j.phymed.2026.158706

Vancouver

Zhang W, Wang AZ, Li X, Kang MJ, Liu Q, Tian JR, et al. (+)-Magnoflorine suppresses osteoclastogenesis by regulating CCDC88A-associated signaling networks in estrogen-deficient osteoporosis. Phytomedicine. 2026. doi:10.1016/j.phymed.2026.158706

BibTeX
@article{Zhang2026,
  author = {Zhang, Wei and Wang, An-Zhu and Li, Xiang and Kang, Meng-Jiao and Liu, Qian and Tian, Jing-Ru and Li, Xiang-Yan and Wang, Ze-Yu and Zhao, Jin-Yue and Fan, Jia-Xing and Wang, Shan and Qin, Li-Hua and Tong, Xiao-Lin and Zhao, Lin-Hua},
  title = {(+)-Magnoflorine suppresses osteoclastogenesis by regulating CCDC88A-associated signaling networks in estrogen-deficient osteoporosis},
  journal = {Phytomedicine},
  year = {2026},
  doi = {10.1016/j.phymed.2026.158706}
}
Kostenlos starten →